John GustofsonManaging Director at AbbVie Ventures
John Gustofson is a Managing Director of AbbVie Ventures and invests across AbbVie’s therapy areas of Immunology, Oncology, and Neuroscience. He currently serves on the Board of Ribometrix and Rheostat and is a Board Observer for Disarm Therapeutics and Ribon Therapeutics.
Prior to joining AbbVie, John worked at AstraZeneca as a Director of Strategic Partnering and Business Development focused on oncology licensing. John has 20+ years professional experience as a bench scientist and in various roles of market and business development. In addition John has worked in numerous biotechnology companies including Altus Pharmaceuticals, Therion Biologics, Boston Life Sciences and Ribozyme Pharmaceuticals. John also spent approximately 4 years in strategy consulting to the life sciences industry.
He holds a Master Degree in Molecular Biology from the Miami University and an MBA from the Boston University.